TB: first new drug in 50 years

March 25, 2010 01:39 am | Updated November 17, 2021 05:50 am IST

Researchers at Sydney's Centenary Institute announced they have made an exciting discovery that could lead to the first new drug for Tuberculosis (TB) in almost fifty years. The discovery comes on the World TB Day.

Dr Nick West, Associate Faculty of the Mycobacterial group at Centenary, is looking at the genetics of TB in the hope they will reveal a way to reduce the impact of one of the deadliest diseases in the world.

Dr West, explains, “When someone is infected with TB they either become sick immediately or the disease stays inactive, latent.”

“Unfortunately, the antibiotics we use to fight TB aren't effective against latent TB and can only be used when the disease becomes active. This is a major problem as 1 out of 10 people who have latent TB will develop the active disease, becoming sick and contagious.”

Dr West and his team have made a vital discovery in the development of a new drug that could cure TB in the latent stage. If the project succeeds, it will be the first new treatment for TB since 1962.

TB kills almost 2 million people each year. One third of the world's population, or two billion people, are infected with TB.

Dr West explains, “We have investigated a protein that is essential for TB to survive and we have had some success in developing a drug that will inhibit this protein. Our goal over the coming months is to find out the full extent of this drug's potential.”

“If we can figure out a way to treat TB when it's in a latent stage, then we could save millions of lives throughout the world.”

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.